US 12,357,627 B2
Pharmaceutical compositions of cabozantinib
Sushant Omprakash Dube, Maharashtra (IN); Suprit Dilip Saoji, Maharashtra (IN); Pankaj Kisan Chatki, Telangana (IN); Sumitra Ashokkumar Pillai, Telangana (IN); and Girish G. Kore, Maharashtra (IN)
Assigned to AZURITY PHARMACEUTICALS, INC., Woburn, MA (US)
Filed by AZURITY PHARMACEUTICALS, INC., Woburn, MA (US)
Filed on Sep. 30, 2024, as Appl. No. 18/901,359.
Application 18/901,359 is a continuation of application No. 18/312,857, filed on May 5, 2023, granted, now 12,138,255.
Application 18/312,857 is a continuation of application No. 18/108,423, filed on Feb. 10, 2023, granted, now 11,679,105, issued on Jun. 20, 2023.
Application 18/108,423 is a continuation of application No. 17/673,583, filed on Feb. 16, 2022, granted, now 11,590,122, issued on Feb. 28, 2023.
Claims priority of application No. 202141007078 (IN), filed on Feb. 19, 2021.
Prior Publication US 2025/0025456 A1, Jan. 23, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/47 (2006.01); A61K 9/10 (2006.01)
CPC A61K 31/47 (2013.01) [A61K 9/10 (2013.01)] 18 Claims
 
1. A pharmaceutical composition suitable for oral administration
comprising a therapeutically effective amount of cabozantinib in the form of an amorphous solid dispersion and at least one pharmaceutically acceptable excipient,
wherein said amorphous solid dispersion consists of
a) cabozantinib or a pharmaceutically acceptable salt thereof;
b) a pharmaceutically acceptable carrier;
c) a pore-forming agent selected from group consisting of hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), lactose, mannitol, and mixtures thereof; and
d) a plasticizer,
wherein said composition can be administered to a human subject without regard to food.